✦ LIBER ✦

492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)

✍ Scribed by M.W Fried; Y.E. Liaw; K.X. Luo; G.K.K. Lau; T. Piratvisuth; G. Cooksley; P. Marcellin; R. Flisiak; M. Popescu; P. Button

Book ID: 117374769
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 124 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80492-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

49 Association between HBeAg seroconvers

49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

✍ T. Piratvisuth; G.K.K. Lau; P. Marcellin; W.C. Chow; G. Cooksley; M.W. Fried; S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

491 Peginterferon alpha-2a (40KD) (PEGAS

491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB)

✍ G. Cooksley; G.K.K. Lau; P. Marcellin; T. Piratvisuth; E. Bonino; K.X. Luo; S. H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 251 KB

HBeAg and hepatitis B virus DNA as outco

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

✍ Michael W. Fried; Teerha Piratvisuth; George K. K. Lau; Patrick Marcellin; Wan-C 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 2 views

The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures o

Evidence for the efficacy of peginterfer

Evidence for the efficacy of peginterferon alfa-2a (40 KD) (PEGASYS) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors

✍ W.Graham E. Cooksley; Teerha Piratvisuth; Yuan-Jen Wang; Varocha Mahachai; You-C 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Predicting HBEAG loss by HBV DNA early k

Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)

✍ A.U. Neumann; Y. Havlin; T. Ronen; M. Tsiang; M. Wulfsohn; C. Brosgart; J. Fry; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 148 KB

HBV DNA suppression in HBeAg-positive ch

HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo

✍ Bettina E. Hansen; Vincent Rijckborst; Martijn J. ter Borg; Prof. Harry L.A. Jan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

## Abstract The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomize